RecruitingNCT06085937
Single-dose ketamine for people with acute suicidal thoughts in the emergency department
About this title
Read the official source — NCT06085937Medication studyAges 18–65United StatesSuicide prevention
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
What will I do during this study?
The study group receives ketamine as a study medication.
- Listed locations
- Kansas City and 1 more locationSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: May 1, 2024
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 50
- Sponsor
- Lindsay Maguire, MD
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06085937
- Official title
Show the full official title
Feasibility and Safety of Single Dose Ketamine for Acutely Suicidal Patients in the Emergency Department
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Kansas City
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Lindsay Maguire, MD.
Does this study involve medication?
Yes. The study involves medication, including ketamine.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
